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Somatic mutation of ten-eleven translocation 2 (TET2) gene is frequently found in human myeloid
malignancies. Recent reports showed that loss of Tet2 led to pleiotropic hematopoietic abnormalities
including increased competitive repopulating capacity of bone marrow (BM) HSCs and myeloid
transformation. However, precise impact of Tet2 loss on the function of fetal liver (FL) HSCs has not been
examined. Here we showthat disruption of Tet2results in the expansionof Lin
2Sca-1
1c-Kit
1 (LSK) cells in
FL.Furthermore,Tet2lossledtoenhancedself-renewalandlong-termrepopulatingcapacityofFL-HSCsin
in vivo serial transplantation assay. Disruption of Tet2 in FL also led to altered differentiation of mature
blood cells, expansion of common myeloid progenitors and increased resistance for hematopoietic
progenitor cells (HPCs) to differentiation stimuli in vitro. These results demonstrate that Tet2 plays a
critical role in homeostasis of HSCs and HPCs not only in the BM, but also in FL.
M
yelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN) are two major hematopoietic
malignancies, thought to arise from hematopoietic stem or progenitor cells. MDS is characterized by
dysregulated hematopoietic differentiation with propensity to develop acute myeloid leukemia(AML)
1.
MPN is a spectrum of disease characterized by the expansion of maturing hematopoietic elements with minimal
dysplasia. Some of the patients with MPN also progress to myeloid leukemia by acquiring additional mutations
altering differentiation. Recent advances in high throughput genome-wide sequencing have made it possible to
identify a number of recurrent somatic mutations in human MDS and MPN. One of the most frequently found
mutations is a loss-of-function mutation of ten-eleven translocation 2 (TET2), which is located at chromosome
4q24 where uniparental disomy was frequently observed in human myeloid malignancies. Recurrent TET2
mutation was identified in 10–20% of MDS and MPN
2,3, and subsequent studies reported high incidence of
TET2 mutations in secondary AML (20–40%) and chronic myelomonocytic leukemia (CMML) (40–50%)
4,5.
These results underscore the importance of TET2 in maintaining homeostasis and malignant transformation of
hematopoietic system.
DNA methylation is one of the most important epigenetic modifications, and aberrant DNA methylations are
hallmark of cancers including AML
6. It was recently reported that TET family proteins could convert 5-methyl-
cytosine(5 mC)to5-hydroxymethylcytosine(5 hmC)
7–9and5 hmCproductionbyTet1iscriticalforEScellself-
renewal and inner cell mass specification
8,10. Moreover, TET2 mutations associated with myeloid malignancies
disrupt its catalytic activity, and BM cells from patients with TET2 mutations contained lower levels of 5 hmC
compared to normal controls
9. On the other hand, mutations of isocitrate dehydrogenase (IDH) 1 and IDH2,
enzymes involved in citrate metabolism, are seen in AML and brain tumors in mutually exclusive manner with
TET2
11–14. These mutations inhibit catalytic activity of TET2 by 2-hydroxyglutarate (2-HG), an oncometabolite
generatedbymutantIDH1/2
14.TET2isdependentonalpha-keto-glutarate(a-KG)foritscatalyticactivity,and2-
HG has been shown to inhibit TET2 by competing with a-KG
15. These results strongly suggest that impaired
5 hmC generation by mutant TET2 or by mutant IDH1/2 is one of the critical steps in myeloid transformation.
FL-HSCsandadultHSCsdifferinseveralaspectsoftheirphenotypesandfunctions.Forexample,FL-HSCsare
differentfromadultHSCsintheexpressionofCD11b/Mac-1andCD34,whilesomemarkerssuchasCD150and
endomucin are commonly expressed in both populations
16,17. FL-HSCs have higher, more robust capacity to
reconstitute hematopoietic compartment in irradiated recipients as compared to adult HSCs
18,19. Moreover,
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differsbetweenFLandadultHSCsasmarkedbydistinctdependence
on polycomb group proteins such as Bmi-1, Rae28, and Mel-18
20–22.
TheseobservationsclearlyindicatethatFL-HSCsandadultHSCsare
phenotypically and functionally distinct, and suggest that they may
be regulated by distinct molecular machinery.
ItwasrecentlyreportedthatinactivationofTet2inmousegenome
resultsinincreasedlong-termrepopulatingcapacityandcompetitive
advantage of HSCs from adult BM, and eventually leads to myeloid
transformation
23–25. However, self-renewal capacity of HSCs was not
precisely assessed by serial transplantation assay and effects of Tet2
disruption on FL-HSCs have not been examined. Here we show that
disruption of Tet2 leads to the expansion of lineage negative (Lin
2),
Sca-1
1, c-Kit
1 (LSK) multipotent progenitor (MPP) fraction and
common myeloid progenitors (CMPs) in FL. In addition, self-
renewal and long-term repopulating capacities were enhanced by
Tet2 disruption as evidenced by serial transplantation assay. These
results clearly indicate critical roles of Tet2 in homeostasis of HSCs
and HPCs in FL.
Results
Characterization of Tet2 gene-trap mice. Tet2 gene was disrupted
by inserting LacZ/ neomycin resistance (b-geo) cassette in intron 2,
just before exon 3 (Figure 1A). mRNAs transcribed from the
endogenous promoter are expected to terminate by being spliced
to the trap cassette, which carries poly A signal at the end. Since
exon 3 is the first coding exon, trapping the Tet2 message before
exon 3 should lead to complete ablation of Tet2. We first tested
whether mRNA was efficiently terminated by the trap-cassette.
Semi-quantitative and real-time quantitative RT-PCR using
primers amplifying exon 1–3 revealed that mRNA reading through
exon 3 in Tet2
gt/gt mice was far less than 1% of that of Tet2
1/1 mice,
indicating that almost all mRNAs were trapped by the cassette
(Figure 1B and C). Of note, the level of mRNA in Tet2
1/gt mice
was approximately 20% of WT. We have also examined the
catalytic activity of TET2 in gene-trap mice by dot blot assay.
Quantification of the 5 mC and 5 hmC levels in DNA from FL
cells confirmed a marked reduction of 5 hmC signals in Tet2
gt/gt
mice as compared to WT (Figure 1D). These data indicate that
transcription of Tet2 gene was efficiently disrupted in Tet2
gt/gt
mice, and therefore, Tet2
gt allele can be regarded as a null allele.
Asreportedpreviously,intercrossofheterozygousmiceresultedin
perinatal lethality of homozygous mice, and very few Tet2
gt/gt mice
survived to 1 week after birth
26. Therefore, we used fetal liver (FL)
cells for analyzing hematopoiesis for the following analysis.
Tet2 disruption leads to the expansion of multipotent progenitor
cells and myeloid progenitors in fetal liver. Initial analysis revealed
that the numbers of whole FL cells or various hematopoietic
progenitors in FLs were not significantly different between WT
and Tet2-mutant embryos (Supplemental Figure S1 A and B).
In addition, apoptotic status of FL cells as shown by the staining
with annexin V and propidium iodide (PI) was indistinguishable
between WT and Tet2-mutants (Supplemental Figure S2). Next we
analyzed the frequency and numbers of hematopoietic stem and
progenitor cells in Tet2-mutant FLs. Interestingly, percentage of
lineage negative (Lin
2), Sca-1
1, c-Kit
1 (LSK) fraction that mainly
consistsofMPPs increased inTet2
gt/gt(1.451/20.62%) andTet2
1/gt
FLs (1.21 1/2 0.43%) as compared to wild-type (WT) (0.85 1/2
0.34%) FLs (Figure 2A and B). Absolute number of LSK cells
was also increased in Tet2-mutant FLs (Suppl. Figure S3A).
However, percentages and absolute numbers of CD150
1LSK,
CD150
1CD48
2LSK and CD34
1LSK cells, highly enriched fractions
of FL-HSCs, were not statistically different between WT and Tet2
mutants (Figure 2A and B, Suppl. Figure S3A). Analysis of myeloid-
committed progenitor cells revealed that the frequency of common
myeloid progenitors (CMPs) significantly increased in Tet2
gt/gt FLs,
whereas those of granulocyte-monocyte progenitors (GMPs) and
megakaryocyte-erythroid progenitors (MEPs) did not (Figure 2A
and C). The average cell number of Tet2
gt/gt CMPs was higher
than that of WT or Tet2
1/gt CMPs, although the difference was
not statistically significant (Suppl. Figure S3B). Taken together,
disruption of Tet2 leads to the expansion of LSK cells and CMPs,
but not highly purified HSCs in FLs.
Self-renewal capacity of HSCs was dramatically enhanced by
ablation of Tet2. Increased LSK fraction in Tet2
gt/gt FLs with
expansion of the MPP population could be due to enhanced self-
renewal capacity of FL-HSCs upon disruption of Tet2. To address
this issue, we performed serial transplantation assay using FL cells
fromWTandTet2-mutantembryos(Figure 3A).Transplantation of
1x1 0
6 FL cells with 2 x 10
5 competitor cells into lethally irradiated
recipients resulted in over 80% peripheral engraftment in all
genotypes. Strikingly however, secondary and tertiary transplant
led to dramatically increased peripheral blood (PB) chimerism of
Tet2
gt/gt cells compared to WT cells. Interestingly, chimerism of
Tet2
1/gt cells was intermediate between WT and Tet2
gt/gt which was
statisticallyhighercomparedtoWTinthesecondaryandthetertiary
transplants, while the difference to Tet2
gt/gt cells was not statistically
significant. We speculated that FL-HSCs might expand in the
engrafted microenvironment, and therefore went on to examine
the fraction of donor-derived HSCs in the recipients’ bone marrow
(BM). As expected, percentage of donor-derived HSCs (CD34
2LSK
cells) in the recipient’s marrow was significantly higher in Tet2
gt/gt
group (0.85 1/2 0.16%) compared to WT (0.49 1/2 0.18%)
(Figure 3B). Tet2
1/gt CD34
2LSK cells again showed intermediate
expansion (0.74 1/2 0.11%), the difference of which was not
statistically significant against WT or Tet2
gt/gt cells. To investigate
whether enhanced engraftment of Tet2-mutant FL cells was due to
the increased number or enhanced long-term repopulating (LTR)
andself-renewalcapacityofFL-HSCs,wetransplantedequalnumber
of highly purified FL-HSCs (CD34
1LSK cells) from WT or Tet2
gt/gt
embryos with competitor cells and examined their engraftment
in the recipients’ PB (Suppl. Figure S4). Interestingly, Tet2
gt/gt
CD34
1LSK cells showed higher engraftment as compared to WT
cells, indicating that LTR/ self-renewal capacity of FL-HSCs was
enhanced by Tet2-loss.
Taken together, these results clearly indicate that LTR and self-
renewal capacity of FL-HSCs is enhanced by disruption of Tet2,
and they can expand in the BM microenvironment of transplanted
recipients.
Disruption of Tet2 impairs myeloid differentiation. In serial
transplantation experiment, multilineage differentiation potential
of Tet2-mutant FL cells was grossly maintained throughout trans-
plants. However, close examination of peripheral blood (PB) by
flow cytometry revealed some alteration of myeloid differentia-
tion in Tet2-mutant cells. Interestingly, significant decrease of
Gr-1
1CD11b
1 mature granulocytes was observed in both primary
and secondary recipients of Tet2
gt/gt cells (Figure 4A and B), while
F4/80
1CD11b
1 monocytes were not affected (Figure 4A and C). Of
note, we observed slight increase of mature B cells accompanied by
slight decrease of mature T cells in Tet2
gt/gt cells, whose significance
must be substantiated by further investigation (Figure 4A). Taken
together, these data suggest that disruption of Tet2 not only affects
HSC function, but also impose a significant defect on myeloid
differentiation.
Tet2 loss confers hematopoietic progenitor cells with resistance
to differentiative stress. Enhanced self-renewal capacity is often
accompanied by resistance to differentiating stimuli. We tested this
hypothesis by culturing FL cells from WT or Tet2-mutant embryos
under a differentiative condition and examined their surface
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 273 | DOI: 10.1038/srep00273 2phenotype by flow cytometry (Suppl. Figure S5A). The rate of
proliferation was comparable between each genotypes (Suppl.
Figure S5B). As shown in Figure 5, Tet2
gt/gt FL cells contained
higher fraction of immature cells such as LSK (Figure 5A and B),
Lin
2 and c-Kit
1 cells (Figure 5A and C) as compared to WT after a
liquid culture for 7-days with cocktails of cytokines. Surprisingly,
percentage and absolute number of LSK fraction of Tet2
gt/gt cells
did not drop after 7-days of culture, while the latter of Tet2
1/1
and Tet2
1/gt cells decreased approximately by half (Figure 5B).
These results strongly suggest that Tet2 loss confers immature
hematopoietic cells in FL with resistance to differentiation in in
vitro culture condition.
Figure 1 | Schematic illustration of Tet2 gene-trap allele and validation of Tet2 ablation. (A) Schematic illustration of Tet2 gene-trap allele. SA; mouse
En2 splicing acceptor site, b-geo; b-galactosidase/ neomycin-resistance fusion gene, LacZ; b-galactosidase, Neo; neomycin phosphotransferase, polyA;
polyadenylation signal. Detailed structure and feature of gene-trap vector was described previously
26,31. Arrows indicate the primers used for RT-PCR.
Red broken lines are mRNA transcribed from the endogenous promoter. Red circle shows that mRNA is terminated by poly A signal in the trap cassette.
(B) Efficiency of Tet2 mRNA knockdown by RT-PCR. RT-PCR was performed as described in Methods using cDNAs derived from Tet2
1/1 and Tet2
gt/gt
fetallivercells.PCRwasrunfor35cycles.ThepositionsofforwardandreverseprimersareshowninFigure1A.cDNAfromiPScellswasusedforpositive
control. The electrophoretic gels for Gapdh are cropped. Uncropped images ofthe full-length gels are presented in Supplementary Figure 8. PC; positive
control,NC;negativecontrol.(C)EfficiencyofTet2mRNAknockdownbyquantitativeRT-PCR.qRT-PCRwasperformedasdescribedinMethodsusing
cDNAs derived from Tet2
1/1, Tet2
1/gt and Tet2
gt/gt fetal liver cells. The positions of forward and reverse primers are shown in figure 1A. Expression was
normalized to the expression level of Gapdh in each fetal liver cells. The data represents the mean 6 standard deviation (S.D.) (n53 for each genotype).
(D) Quantification of 5 mC and 5 hmC levels in DNA from FL cells by dot blot assay. Genomic DNA was spotted onto the membrane at the amount
indicated on the left. DNA extraction and immunoblot were performed as described in Methods.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 273 | DOI: 10.1038/srep00273 3Figure 2 | CharacterizationofHSC,HPCandmyeloidprogenitorfractionsinfetalliversofTet2gene-trapmice. (A)FlowcytometricanalysisofHSC/
HPC fractions (LSK, CD150
1LSK, CD150
1CD48
2LSK) and myeloid progenitor fractions (CMP, GMP, MEP) in FLs was performed as described in
Methods.Representativefiguresforeachgenotypeareshown.Thedatarepresentsthemean6S.D.foreachfraction(LSK;Tet2
1/1:n514,Tet2
1/gt:n523,
Tet2
gt/gt:n 511, CD150
1LSK, CD150
1CD48
2LSK, and myeloid progenitors; n53 for each genotype). (B and C) Percentages of each HSC/HPC fractions
(B) or each myeloid progenitor fractions (C) within whole FL cells. The data represents the mean 6 S.D. for each fraction (LSK; Tet2
1/1:n 514, Tet2
1/gt:
n523, Tet2
gt/gt:n 511, CD150
1LSK, CD150
1CD48
2LSK, and myeloid progenitors; n53 for each genotype).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 273 | DOI: 10.1038/srep00273 4Figure 3 | Serial transplantation of Tet2-mutant fetal liver cells. (A) WT and Tet2-mutant FL cells (Ly5.2) were transplanted into lethally irradiated
recipients (Ly5.1), and percentages of donor chimerism in recipient’s PB were analyzed by flow cytometry at the indicated time points after
transplantation.SerialtransplantationswereperformedasdescribedinMethods.Thedatarepresentsthemean6S.D.(1
sttransplantation;Tet2
1/1:n54,
Tet2
1/gt and Tet2
gt/gt:n 55, 2
nd and 3
rd transplantation; Tet2
1/gt:n 54, Tet2
1/1 and Tet2
gt/gt:n 55). (B) (Upper panel) Flow cytometric analysis of donor
derived HSC fraction (CD34
2LSK cells) within Lin
2 fraction of BM mononuclear cells in mice receiving the first transplants. Representative FACS
picturesareshown.(Lowerpanel)PercentagesofdonorderivedCD34
2LSKcellswithinLin
2fractionofBMmononuclearcellsinmicereceivingthefirst
transplants. The data represents mean 6 S.D. (n53 for each recipient).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 273 | DOI: 10.1038/srep00273 5Figure 4 | Differentiation of Tet2-mutant FL cells in transplanted recipient mice. Fractions of mature granulocytes (Gr-1
1CD11b
1), monocytes
(F4/80
1CD11b
1) and lymphocytes (B220
1 or CD3
1) in mice transplanted with WT or Tet2-mutant FL cells were analyzed at 12 weeks after the 1
st or 2
nd
transplantationbyflowcytometry.Thedatarepresentsthemean6S.D.(1
sttransplantation;Tet2
1/1recipient:n54,Tet2
1/gtandTet2
gt/gtrecipient:n55,
2
nd transplantation; Tet2
1/gt recipient : n54, Tet2
1/1 and Tet2
gt/gt recipient : n55). (A) Representative FACS pictures are shown. (B, C, D) Percentages of
granulocytes (B), monocytes (C), and B or T cells (D) are shown on the graphs. The data are mean 6 S.D.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 273 | DOI: 10.1038/srep00273 6Figure 5 | Tet2-mutant FL cells are resistant to differentiative stress in liquid culture. WT or Tet2-mutant FL cells were cultured for 7-days with various
cytokines (rmSCF, rmIL-6, rhFLT3L, rhTPO, and rmIL-3), and LSK, Lin
2 and c-Kit
1 cells were analyzed by flow cytometry as described in the Methods.
(A)Representative FACS pictures ofthe cells after the cultures are shown. The data are mean6 S.D.(n53 for each genotype). (B) Percentages and absolute
cell numbers of LSK cells before and after liquid culture for 7-days with various cytokines (rmSCF, rmIL-6, rhFLT3L, rhTPO, and rmIL-3). The data are
mean 6 S.D. (n53 for each genotype). (C) Percentages of Lin
2 or c-Kit
1 cells after liquid culture for 7-days. The data are mean 6 S.D. (n53 for each
genotype).
www.nature.com/scientificreports
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gene-trap mice. It was reported that myeloproliferation and
extramedullary hematopoiesis occurred with age in Tet2
2/2 and
Tet2
1/2 mice
23,24.S i n c eTet2
gt/gt mice did not survive to adulthood,
we examined Tet2
1/gt mice for evidence of myeloproliferation.
Consistent with the previous reports, white blood cell (WBC) count
in PB was significantly increased in Tet2
1/gt mice at the age of 38-
weeks (Suppl. Figure S6A). In addition, percentage of LSK fraction in
Tet2
1/gt BM was significantly higher compared to that of WT, while
CD150
1LSK cells and myeloid progenitors were not statistically
different between Tet2
1/gt and WT (Suppl. Figure S6B and C). In
contrast however, signs of extramedullary hematopoiesis such as
splenomegaly or expansion of HPCs in spleen were not evident in
Tet2
1/gt mice, and they did not develop fatal myeloproliferative
disorder during an observation over 40-weeks. It is also interesting
to note that there was no sign of myeloproliferation such as increased
WBC count or expansion of mature myeloid cells in the Tet2
gt/gt FL
cell recipients with more than 80% donor chimerism at least until 12-
weeks after transplantation (Suppl. Figure S7). Taken together, these
data indicate that extensive myeloproliferation is not a frequent
phenomenon in Tet2
1/gt mice or mice transplanted with Tet2
gt/gt FL
cells, and suggest that additional factors must cooperate with Tet2 to
develop myeloid transformation.
Discussion
Accumulating evidence suggests that altered regulation of cytosine
hydroxymethylation is a critical pathogenic event in myeloid malig-
nancies, such as MDS, MPN and AML. TET family proteins are
reported to convert 5 mC to 5 hmC, and TET2 mutations found in
myeloid malignancies disrupt this enzymatic functions. Moreover, it
was recently reported that TET2 catalytic activity was inhibited by
2-hydroxyglutarate, an abnormal catalytic product generated by
mutant IDH1 or IDH2 proteins that are frequently found in myeloid
malignancies. These findings strongly suggest that dysregulation of
5 mC to 5 hmC conversion can be a critical step in myeloid trans-
formation.
We showed that disruption of Tet2 in FL led to increased self-
renewal and LTR capacity of FL-HSCs. Furthermore, LSK fraction
thatmainlyconsistsofMPPsclearlyincreasedinTet2
gt/gtFL,whereas
both percentages and numbers of highly enriched FL-HSC fractions
(CD150
1LSK, CD150
1CD48
2LSK and CD34
1LSK cells) were not
significantly different between WT and Tet2
gt/gt mice. These findings
are consistent with the ones reported recently for BM cells, showing
increasedinvitroserialreplatingcapacityandcompetitiveadvantage
ofTet2
2/2HSCsoverWTcells
23–25.Takentogetherwithourdata,itis
suggested that Tet2 is critical for HSC/ HPC homeostasis in both FL
and adult BM. It should be noted, however, that the previous studies
have only examined competitive repopulating capacity of Tet2
2/2
HSCs in a single round of transplantation, and did not precisely
addressed self-renewal capacity of HSCs by ‘serial’ transplantation.
In contrast, we performed serial transplantation assays and showed
that Tet2
gt/gt FL-HSCs presented dramatically increased PB chimer-
ismoverWTcells insecondary andtertiaryrecipients. Furthermore,
CD34
2LSK HSC fraction derived from Tet2
gt/gt FL was significantly
increased in the recipient’s BM as compared to the one from WT,
indicating that expansion of Tet2
gt/gt HSCs is cell autonomous phe-
nomenon and can occur in the BM microenvironment. Importantly,
Tet2
gt/gt cells showed only a mild impairment in myeloid differenti-
ation. Taken together, these data clearly indicate that self-renewal
capacity of FL-HSC is enhanced by inactivation of Tet2 without
major defects on multilineage differentiation capacity.
Enhanced self-renewal capacity of HSCs by Tet2 inactivation is
compatible with high incidence of TET2 mutation in MDS. MDS is
characterized by an expansion of self-renewing malignant clone,
which ultimately overrides normal hematopoiesis in the BM. Loss-
of–function mutation of TET2 clearly endows HSCs with such
fundamental feature of MDS, setting a molecular basis for acquiring
additional mutations and disease progression. Since Tet2 mutation
causes only a mild impairment in myeloid differentiation, it seems
that clonal evolution of MDS to overt leukemia must include a step
acquiring mutation that blocks differentiation.
We have also shown that CMP fraction, but not GMP and MEP,
was significantly increased to 9.04 1/2 1.09% in Tet2
gt/gt FL, as
compared to 6.26 1/2 0.53% in WT. Two recent studies have
describedincreasedpercentageofCMPandGMP,orincreasedabso-
lute number (but not percentage) of CMP and MEP in the Tet2
2/2
BM
23–25. Despite some differences in amplifying cell types, CMP
amplification is commonly observed either in FL or in the BM.
This is in fact consistent with high incidence of TET2 mutation in
human myeloid tumors such as chronic myelomonocytic leukemia
(CMML), which is characterized by extensive myeloproliferation
andmyelodysplasia.Recentstudiesactuallyreportedextramedullary
hematopoiesis and the following myeloid transformation in Tet2
2/2
mice that was reminiscent of human CMML
23–25. They showed peri-
pheral leukocytosis and splenomegaly with proliferation of myeloid
elements occurring in aged mice. Although we could not examine
adult Tet2
gt/gt mice due to their perinatal lethality, analysis of Tet2
1/gt
mice over 30-weeks of age showed a significant increase of WBC
counts in PB. However, in contrast to their results, expansion of
HSCs/ HPCs and myeloid cells in spleen could not be documented
in Tet2
1/gt mice. Phenotypic discrepancies between the studies also
exist in differentiation of myeloid cells in PB. We observed impaired
differentiation of Tet2
gt/gt FL cells to Gr-1
1CD11b
1 mature granulo-
cytes in the transplanted recipients (Figure 4), whereas previous
studies have shown the increase of mature granulocytes in PB of
Tet2
2/2 mice
23–25. On the other hand, shRNA-mediated knockdown
of Tet2 or introduction of mutant IDH2 into murine BM cells
resulted in decreased differentiation to granulocytes
14, which is con-
sistentwithourdata.ThesedatasuggestthattheeffectofTet2losson
myeloid differentiation can be affected by various experimental fac-
torsincludingthestrategiesforTet2targeting,thecellsource(BMvs.
FL) and levels of Tet2 expression. It is clear that disruption of Tet2
criticallyaffectsearlyand latestages ofmyeloiddifferentiation, how-
ever, revealing the precise molecular mechanism of myeloid regu-
lation by Tet2 awaits future investigations.
Epigenetic modification is a fundamental process for stem cells to
maintain pluripotency and capacity to self-renew. Although TET
family protein is a major player in this process, the way in which
they regulate self-renewal seems different between cell types or
among family members. Tet1 is essential for self-renewal and main-
tenanceofEScells(ESCs)asshownbyshRNA-mediatedknockdown
studies, and therefore it has a ‘positive’ regulatory role in this pro-
cess
8. Interestingly however, Tet2 is clearly a ‘negative’ regulator for
self-renewal of HSCs as revealed by the present study and others.
Therefore, while both Tet1 and Tet2 are critical for stemness, they
work in opposite manner in regulating self-renewal. This may be the
reflection of different cellular environment (such as epigenetic sta-
tus) between ESCs and HSCs, or due to the different inherent func-
tion of Tet1 and Tet2. Revealing the molecular targets of these genes
is absolutely essential for answering these questions.
In summary, we showed that Tet2 inactivation in FL resulted in
enhanced LTR and self-renewal capacity of FL-HSCs and altered
differentiationinmyeloidlineage.Currentdataindicatethatconver-
sion of 5 mC to 5 hmC as well as 5-formylcytosine and 5-carbox-
ylcytosine
27 is a key enzymatic function of Tet2 in HSC regulation.
However, there still might be unknown features of Tet2 that are
essential for these processes. Moreover, recent study suggests that
the role of TET proteins is not a mere transcriptional de-repressor,
but they fine-tunes transcription either positively or negatively, act-
ing as global regulators of transcription
28. Further studies are defi-
nitely required to elucidate precise molecular mechanism by which
TET2 regulates HSC stemness and hematopoietic differentiation.
www.nature.com/scientificreports
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Mice. C57BL/6 (B6) mice were from Japan CLEA Inc. (Tokyo, Japan), and B6-Ly5.1
mice were from Sankyo Lab Service Co. (Tsukuba, Japan). Tet2 gene trap mice were
described previously
26. All mice were housed and maintained under specific
pathogen-free (SPF) condition. E14.5 embryos were used in all FL experiments. All
animal experiments were reviewed and approved by the Internal Review Board of
Keio University School of Medicine.
RT-PCR. Total RNA was extracted from FL cells using a TRIZOL Reagent
(Invitrogen) accordingtothemanufacturer’sprotocol. RNAwastreatedwithRNase-
free DNase I (Invitrogen) to remove contaminating genomic DNA. cDNA was
reverse-transcribed using SuperScript II reverse transcriptase (Invitrogen). The
quantity of cDNA was normalized according to the expression of GAPDH measured
by real-time RT-PCR using a THUNDERBIRD SYBRqPCR Mix kit (TOYOBO) and
StepOnePlus
TM real-time PCR system (Applied Biosystems). Real-time PCR was
peformed according to the manufacturer’s protocol. Semi-quantitative RT-PCR was
performed using Ex Taq–HS polymerase (TaKaRa Bio) as described previously
29.
Dot blot assay. Genomic DNA was extracted from FL cells using a DNeasy Blood &
Tissue Kit (QIAGEN) according to the manufacturer’s protocol. DNA amount was
measured using SmartSpec 3000 (BIO-RAD). DNA was manually spotted onto
PROTRANBA85nitrocellulosemembranes(Schleicher&Schuell).Membraneswere
first probed with anti-5-methylcytidine antibody (Eurogentec) or anti-5-
hydroxymethylcytidine antibody (Active Motif), which were then probed with
horseradish peroxidase (HRP)-conjugated anti-mouse immunoglobulin (Ig)
polyclonal antibody. Bound antibodies were visualized by enhanced
chemiluminescence (ECL; Amersham).
Analysis of fetal liver cells by flow cytometry. For the analysis of hematopoietic
stem/progenitor cells and myeloid progenitor cells in FLs, FLs were dissected from
E14.5 embryos and single cell suspension was made in phosphate-buffered saline
(PBS). After lysing red blood cells in ACK lysis buffer (0.15 M NH4Cl, 10 mM
KHCO3,0.1 mMNa2EDTA)at37uCfor5minutes,cellswerespunandsuspendedin
PBS supplemented with 5% fetal bovine serum (FBS). For HSC/ HPC (LSK,
CD150
1LSK, CD150
1CD48
2LSK) analysis, cells were stained with biotin anti-B220
(RAE-6B2, e-Bioscience), biotin anti-CD19 (6D5, BioLegend), biotin anti-Ter119
(TER-119, e-Bioscience), biotin anti-Gr-1 (RB6-8C5, BioLegend), phycoerythrin
(PE)-Sca-1 (D7, e-Bioscience), allophycocyanin (APC)-c-Kit (2B8, e-Bioscience),
Alexa488-CD150 (TC15-12F12.2, BioLegend), and biotin anti-CD48 (HM48-1,
BioLegend), followed by staining with streptavidin-PE-Cy7 (BioLegend). For the
analysis of myeloid progenitor cells (CMP, GMP, MEP), cells were stained with
fluorescein isothyocyanate (FITC)-CD34 (RAM34, BD Pharmingen), PE-FccRII/III
(2.4G2,BDPharmingen),APC-c-Kit,biotinanti-B220,biotinanti-CD19,biotinanti-
Ter119, biotin anti-Gr-1, biotin anti-IL7Ra (A7R34, e-Bioscience) and biotin anti-
Sca-1 (D7, BioLegend), followed by staining with streptavidin-PE-Cy7. Stained cells
were analyzed by MoFlo (Beckman Coulter) or FACS Calibur (BD Bioscience).
Analysisofdonor-derivedmaturebloodcellsandBMHSCsaftertransplantation.
Percentages of donor chimerism together with differentiation to multiple lineages in
recipient’s PB were analyzed by flow cytometry at 4, 8, and 12 weeks after
transplantation. After lysisofredbloodcells,totalwhitebloodcellswerestainedwith
peridinin-chlorophyll proteins-cyanin 5.5 (PerCp-Cy5.5)-CD45.2 (104, BioLegend),
or combination of the following monoclonal antibodies: FITC-Gr-1 (RB6-8C5, BD
Pharmingen), PE-CD11b (M1/70, BD Pharmingen), FITC-F4/80 (BM8, BioLegend),
FITC-B220 (RA3-6B2, BioLegend), and PE-CD3 (145-2C11, e-Bioscience). For
analyzing donor-derived HSCs in the BM, cells were collected from bilateral femurs
and tibias of the recipient mice 20 weeks after transplantation. Mononuclear cells
were separated by density-gradient centrifugation using Lymphoprep (Axis-Shield
Poc AS), and lineage-positive cells were depleted using Lineage Cell Depletion Kit
(Miltenyi Biotec) according to the manufacturer’s protocol. CD34
2LSK cells were
analyzed as described previously
30. Briefly, lineage-negative cells were stained with
FITC-CD34 (RAM34, BD Pharmingen), APC-Cy7-CD45.1 (A20, BioLegend),
PE-Sca-1 (D7, e-Bioscience), APC-c-Kit (2B8, e-Bioscience), and an anti-lineage
antibody cocktail in the Lineage Cell Depletion Kit, followed by staining with
streptavidin-PE-Cy7. Cells were analyzed by FACS Calibur and MoFlow cytometer.
Serialtransplantationassay.FLcellswereseparatedfromE14.5embryos(Ly5.2)and
suspendedinIMDMsupplementedwith10%FBS,100 U/mlpenicillin G,100 mg/ml
streptomycin, 50 mg/ml gentamicin and 2 mM L-glutamine. Competitor cells were
collected from the BM of 7-week-old Ly5.1 mice. 1310
6 whole fetal liver cells (Ly5.2)
with 2310
5 competitor BM cells (Ly5.1) were intravenously injected into lethally
irradiated recipient mice (Ly5.1) through tail veins. For secondary or tertiary
transplantation, 2310
6 whole BM cells taken from the first or secondary recipient
mice 12 weeks after transplantation were transplanted into lethally irradiated
recipient mice (Ly5.1).
In vitro liquid culture assay. Whole FL cells were collected from E14.5 embryos and
suspendedinIMDMsupplementedwith15%FBS,100 U/mlpenicillin G,100 mg/ml
streptomycin, 50 mg/ml gentamicin and 2 mM L-glutamine and cytokines (rmSCF
50 ng/mL, rmIL-6 50 ng/mL, rhFLT3L 50 ng/mL, rhTPO 50 ng/mL, rmIL-3 20
ng/mL).Cellswereculturedinhumidifiedatmospherewith5%CO2at37uC,andsplit
onday2,4,and6tokeepcelldensitybetween5x10
5/mland1x10
6/ml.Cellnumbers
were enumerated on day 2, 4, and 6. Cells were collected on day 7 for the analysis of
LSK, lineage negative, and c-Kit positive cells.
Statistical analysis. All statistical analyses were performed using unpaired Student’s
t-test. P values,0.05 were considered statistically significant.
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